Trillium Therapeutics (Nasdaq: TRIL), the cancer startup that less than two years ago was in danger of being delisted from the Nasdaq, is being acquired by pharmaceutical giant Pfizer Inc. (NYSE: PKE) for $2.26 billion in equity.